The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-06. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Sequence comparisons indicate an evolutionary relationship between gelsolin, villin, fragmin, and severin. Six large repeating segments occur in gelsolin and villin, and 3 similar segments in severin and fragmin. The multiple repeats are related in structure (but barely in sequence) to the ADF-H domain, forming a superfamily (InterPro: IPR029006). The family appears to have evolved from an ancestral sequence of 120 to 130 amino acid residues. Asgard archaea encode many functional gelsolins.
"Fentanyl". U.S. Drug Enforcement Administration (DEA). "Fentanyl". European Union Drugs Agency (EUDA). "Fentanyl". National Institute on Drug Abuse (NIDA). 21 December 2021. Archived from the original on 6 June 2022. Fentanyl (Report). National Institute for Occupational Safety and Health (NIOSH). 8 July 2021.
The chemists used an "atomic mass unit" (amu) scale such that the natural mixture of oxygen isotopes had an atomic mass 16, while the physicists assigned the same number 16 to only the atomic mass of the most common oxygen isotope (16O, containing eight protons and eight neutrons). However, because oxygen-17 and oxygen-18 are also present in natural oxygen this led to two different tables of atomic mass. The unified scale based on carbon-12, 12C, met the physicists' need to base the scale on a pure isotope, while being numerically close to the chemists' scale. This was adopted as the 'unified atomic mass unit'. The current International System of Units (SI) primary recommendation for the name of this unit is the dalton and symbol 'Da'. The name 'unified atomic mass unit' and symbol 'u' are recognized names and symbols for the same unit. The term atomic weight is being phased out slowly and being replaced by relative atomic mass, in most current usage. This shift in nomenclature reaches back to the 1960s and has been the source of much debate in the scientific community, which was triggered by the adoption of the unified atomic mass unit and the realization that weight was in some ways an inappropriate term.
=== Names === Nemonapride is the generic name of the drug and its INNTooltip International Nonproprietary Name and JANTooltip Japanese Accepted Name. It was also previously known as emonapride and by its former developmental code name YM 09151-2. In addition, nemonapride is known by its brand name Emilace (JPTooltip Japanese language: エミレース) in Japan and China.
Sources: en.wikipedia.org
=== Modes of toxicity === Since silver nanoparticles undergo dissolution releasing silver ions, which is well-documented to have toxic effects, there have been several studies that have been conducted to determine whether the toxicity of silver nanoparticles is derived from the release of silver ions or from the nanoparticle itself. Several studies suggest that the toxicity of silver nanoparticles is attributed to their release of silver ions in cells as both silver nanoparticles and silver ions have been reported to have similar cytotoxicity. For example, In some cases it is reported that silver nanoparticles facilitate the release of toxic free silver ions in cells via a "Trojan-horse type mechanism", where the particle enters cells and is then ionized within the cell. However, there have been reports that suggest that a combination of silver nanoparticles and ions is responsible for the toxic effect of silver nanoparticles. Navarro et al. using cysteine ligands as a tool to measure the concentration of free silver in solution, determined that although initially silver ions were 18 times more likely to inhibit the photosynthesis of an algae, Chlamydomanas reinhardtii, but after 2 hours of incubation it was revealed that the algae containing silver nanoparticles were more toxic than just silver ions alone. Furthermore, there are studies that suggest that silver nanoparticles induce toxicity independent of free silver ions. For example, Asharani et al.
The Soviet military maintained control over the space program; Korolev's OKB-1 design bureau was subordinated under the Ministry of General Machine Building, tasked with the development of intercontinental ballistic missiles, and continued to give its assets random identifiers into the 1960s. Information about failures was systematically withheld, historian James Andrews notes that Soviet media coverage of the space program, particularly human space missions, rarely reported any failures or difficulties, creating the impression of a flawless operation:"With almost no exceptions, coverage of Soviet space exploits, especially in the case of human space missions, omitted reports of failure or trouble".Dominic Phelan noted in the book Cold War Space Sleuths (Springer-Praxis 2013): "The USSR was famously described by Winston Churchill as 'a riddle, wrapped in a mystery, inside an enigma' and nothing signified this more than the search for the truth behind its space program during the Cold War. Although the Space Race was literally played out above our heads, it was often obscured by a figurative 'space curtain' that took much effort to see through".
Pakistan, the only country established in the name of Islam, had overwhelming support among Muslims, especially in provinces like the United Provinces, where Muslims were a minority. This idea, articulated by the Muslim League, the Islamic clergy, and Jinnah, envisioned an Islamic state. Jinnah, closely associated with the ulama, was described upon his death by Maulana Shabbir Ahmad Usmani as the greatest Muslim after Aurangzeb, aspiring to unite Muslims worldwide under Islam. The Objectives Resolution of March 1949 marked the initial step towards this goal, affirming God as the sole sovereign. Muslim League leader Chaudhry Khaliquzzaman asserted that Pakistan could only truly become an Islamic state after bringing all believers of Islam into a single political unit. Keith Callard observed that Pakistanis believed in the essential unity of purpose and outlook in the Muslim world, expecting similar views on religion and nationality from Muslims worldwide.
Sources: en.wikipedia.org
ADP + a phosphoprotein Thus, the two substrates of this enzyme are ATP and a protein, whereas its two products are ADP and phosphoprotein. The systematic name of this enzyme class is ATP:protein phosphotransferase (non-specific).
=== Turkevich method === This simple method was pioneered by J. Turkevich et al. in 1951 and refined by G. Frens in the 1970s. It produces modestly monodisperse spherical gold nanoparticles of around 10–20 nm in diameter. Larger particles can be produced, but at the cost of monodispersity and shape. In this method, hot chloroauric acid is treated with sodium citrate solution, producing colloidal gold. The Turkevich reaction proceeds via formation of transient gold nanowires. These gold nanowires are responsible for the dark appearance of the reaction solution before it turns ruby-red.
=== Doping in sport === Phenylpiracetam has stimulant effects and may be used as a doping agent in sport. As a result, it is on the list of stimulants banned for in-competition use by the World Anti-Doping Agency (WADA). This list is applicable in all Olympic sports. Owing to its unique stimulant properties among racetams, phenylpiracetam is the only racetam on the WADA prohibited list.
Dislocations or subluxations (that is, partial dislocations) Sprains, tendinitis, or bursitis from activities. However, a 2018 study reports that while hypermobile individuals are more likely to suffer dislocations doing sports than non-hypermobile individuals, they are less likely to suffer muscle and tendon sprains. The overall chances of sports injury are not significantly different. Joint pain Back pain Joints that make clicking noises Chance of nerve compression disorders in the joints (such as carpal tunnel syndrome) "Growing pains" (as described in children in late afternoon or night)
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.